摘要
整合素受体被认为是致癌的关键因素。αIIbβ3-整合素(GP IIb/IIIa)是血小板表面的主要糖蛋白,它也存在于某些癌细胞系中。其作用于肿瘤细胞的分子机制尚不清楚。本研究提出了两个αIIbβ3-整合素:阿昔单抗和依替巴肽对细胞凋亡的影响,如在MCF-7乳腺癌细胞中对脯氨酸氧化酶(POX)的表达,信号分子ERK 1 / 2,转录因子NF-κB和HIF-1κα,血管内皮生长因子(VEGF)以及DNA的生物合成,的胶原的生物合成和脯氨酸肽酶活性等影响。配体诱导的细胞凋亡,但我们在测试不同αIIbβ3-整合素时发现其分子作用机制存在显著差异。这些差异包括POX, HIF-1α, NF-κB,VEGF的表达,血管内皮生长因子和胶原的生物合成。依替巴肽使MCF-7细胞凋亡的活性比阿昔单抗更强。这项研究的结果表明,依替巴肽可以被认为是一个新的抗癌治疗药物。
关键词: αIIbβ3-整合素,αIIbβ3-整合素,阿昔单抗,依替巴肽,MCF-7乳腺癌细胞,细胞凋亡
图形摘要
Current Drug Targets
Title:αIIbβ3-integrin Ligands: Abciximab and Eptifibatide as Proapoptotic Factors in MCF-7 Human Breast Cancer Cells
Volume: 16 Issue: 13
Author(s): Joanna Kononczuk, Arkadiusz Surazynski, Urszula Czyzewska, Izabela Prokop, Michal Tomczyk, Jerzy Palka and Wojciech Miltyk
Affiliation:
关键词: αIIbβ3-整合素,αIIbβ3-整合素,阿昔单抗,依替巴肽,MCF-7乳腺癌细胞,细胞凋亡
摘要: Integrin receptors are considered to be the key factors in carcinogenesis. αIIbβ3-Integrin (GP IIb/IIIa) is the main glycoprotein of the surface of platelets, its presence has also been noted on the certain cancer cell lines. The molecular mechanism of its action in cancer cells remains unknown. This study presents effects of two αIIbβ3-inhibitors: Abciximab and Eptifibatide on apoptosis, expression of proline oxidase (POX), signaling molecules ERK 1/2, transcription factor NF-κB and HIF-1α, vascular endothelial growth factor (VEGF) as well as DNA biosynthesis, collagen biosynthesis and prolidase activity in MCF-7 breast cancer cells. Both ligands induced apoptosis, however we found significant differences in molecular mechanism of action between tested αIIbβ3-inhibitors. These differences include expression of POX, HIF-1α, NF-κB,VEGF and collagen biosynthesis. Eptifibatide presented stronger proapoptotic activity in MCF-7 cells than Abciximab. Results of this study suggest that Eptifibatide may be considered as a novel candidate for development of new anticancer therapy.
Export Options
About this article
Cite this article as:
Joanna Kononczuk, Arkadiusz Surazynski, Urszula Czyzewska, Izabela Prokop, Michal Tomczyk, Jerzy Palka and Wojciech Miltyk , αIIbβ3-integrin Ligands: Abciximab and Eptifibatide as Proapoptotic Factors in MCF-7 Human Breast Cancer Cells, Current Drug Targets 2015; 16 (13) . https://dx.doi.org/10.2174/1389450115666140804220441
DOI https://dx.doi.org/10.2174/1389450115666140804220441 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
L-Tetrahydropalmatine Induces Apoptosis in EU-4 Leukemia Cells by Down-Regulating X-Linked Inhibitor of Apoptosis Protein and Increases the Sensitivity Towards Doxorubicin
Current Molecular Medicine Ipilimumab and Vemurafenib: Two Different Routes for Targeting Melanoma
Current Cancer Drug Targets Prospects of Nanocarriers for Oral Delivery of Bioactives Using Targeting Strategies
Current Pharmaceutical Biotechnology The Epithelial-Mesenchymal Transition and Cancer Stem Cells: Functional and Mechanistic Links
Current Pharmaceutical Design Cancer Therapy: Targeting Cell Cycle Regulators
Anti-Cancer Agents in Medicinal Chemistry Dimer and Tetramer of Gallic Acid: Facile Synthesis, Antioxidant and Antiproliferative Activities
Letters in Drug Design & Discovery Stress Relaxation Testing of Non-Small Lung Cancer Cells Using Atomic Force Microscopy
Current Nanoscience The Therapeutic Potential of RNA Interference: Novel Approaches for Cancer Treatment
Current Pharmaceutical Biotechnology Clinical, Prognostic and Therapeutic Significance of Heat Shock Proteins in Cancer
Current Drug Targets Diagnostic and Prognostic Value of 18F-FDG PET/CT in Male Breast Cancer: Results From a Bicentric Population
Current Radiopharmaceuticals Does Hypoxic Response Mediate Primary Resistance to Sunitinib in Untreated Locally Advanced Breast Cancer?
Current Cancer Drug Targets Extracellular Vesicles in the Treatment of Parkinson’s Disease: A Review
Current Medicinal Chemistry Synthetic Src-Kinase Domain Inhibitors and Their Structural Requirements
Anti-Cancer Agents in Medicinal Chemistry Persistent GP130/STAT3 Signaling Contributes to the Resistance of Doxorubicin, Cisplatin, and MEK Inhibitor in Human Rhabdomyosarcoma Cells
Current Cancer Drug Targets MDM2 Increases Drug Resistance in Cancer Cells by Inducing EMT Independent of p53
Current Medicinal Chemistry Update on Cancer Related Issues of Mesenchymal Stem Cell-Based Therapies
Current Stem Cell Research & Therapy Role of Genomics-Based Strategies in Overcoming Chemotherapeutic Resistance
Current Pharmaceutical Biotechnology Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Mining PeptideAtlas for Biomarkers and Therapeutics in Human Disease
Current Pharmaceutical Design Clinical Trials with Oncolytic Adenovirus in China
Current Cancer Drug Targets